High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation
复制标题
DOI：
10.3324/haematol.2011.043786
复制
发表时间：
2011-10-01
期刊：
影响因子：
--
通讯作者：
Guarini, Anna
中科院分区：
文献类型：
--
作者：
De Propris, Maria Stefania;Raponi, Sara;Guarini, Anna
CD33抗原在大多数急性髓性白血病病例的母细胞上表达，并且代表用于基于抗体的疗法的合适的肿瘤相关靶抗原。本研究的目的是探讨99例初诊急性髓系白血病患者的CD33水平与NPM1和FLT3基因突变的关系。与NPM1未突变的病例相比，NPM1突变的急性髓性白血病病例中以平均荧光强度和抗体结合能力评估的CD33强度显著更高（分别为P=0.0001和P=0.0088）。相反，FLT3基因突变不影响白血病细胞上的CD 33表达水平。这些结果为抗CD33抗体在NPM1突变的急性髓系白血病患者中的治疗应用奠定了合理的基础。
The CD33 antigen is expressed on the blast cells of most cases of acute myeloid leukemia and represents a suitable tumor-associated target antigen for antibody-based therapies. The aim of this study was to investigate the relationship between the CD33 levels quantified by mean fluorescence intensity and antibody binding capacity, and the presence/absence of NPM1 and FLT3 gene mutations in 99 newly diagnosed acute myeloid leukemia cases. The CD33 intensity evaluated as mean fluorescence intensity and antibody binding capacity was significantly higher in the NPM1-mutated acute myeloid leukemia cases compared to the NPM1-unmutated cases (P=0.0001 and P=0.0088, respectively). On the contrary, FLT3 gene mutations did not influence the levels of CD33 expression on the leukemic cells. These results establish a rational basis for the therapeutic use of anti-CD33 antibodies in NPM1-mutated acute myeloid leukemia patients.